- Albuferon(R) Phase 3 trial in genotype 1 hepatitis C completes treatment
phase - - Enrollment of patients into screening completed in second LymphoStat-B(R) Phase 3 trial in systemic lupus erythematosus; completion of randomization
expected in August 2008 - - Initial data from Phase 2 HGS-ETR1 multiple myeloma study expected in
third quarter 2008 -
ROCKVILLE, Md., July 30 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results and key developments for the quarter ended June 30, 2008.
"During the second quarter, we continued to make excellent progress in our Phase 3 trials of Albuferon(R) in chronic hepatitis C and LymphoStat-B(R) in systemic lupus erythematosus," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "Our timelines to Phase 3 results and the filing of marketing applications are on track for both of these key lead products. Our oncology program also continued to show solid progress. For HGS-ETR1, we expect to have data available from our multiple myeloma trial in the third quarter of 2008, and we will soon complete enrollment in our non-small cell lung cancer trial."
HGS reported increased revenues for the quarter ended June 30, 2008 of
$11.6 million, compared with revenues of $9.0 million for the same period
in 2007. Revenues included $8.9 million recognized from the Albuferon
agreement with Novartis, and $1.6 million in revenue recognized from the
LymphoStat-B agreement with G
|SOURCE Human Genome Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved